Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A three-drug combo is turning heads in ovarian cancer treatment. The phase 2 BELLA trial found that relacorilant (Lifyorli) plus nab-paclitaxel and bevacizumab achieved a 59% response rate and a median progression-free survival of 7.2 months in patients with recurrent, platinum-resistant ovarian cancer. Results were even stronger in patients who had never received bevacizumab before, with a 66% response rate and an 8.1-month median PFS.
A three-drug regimen is showing real promise for one of oncology's toughest challenges. Topline results from Part A of the phase 2 BELLA trial reveal that relacorilant (Lifyorli) combined with nab-paclitaxel (Abraxane) and bevacizumab (Avastin) delivered a 59% objective response rate and a median progression-free survival (PFS) of 7.2 months in 95 patients with recurrent, platinum-resistant ovarian cancer. Median overall survival had not yet been reached, and 88% of patients were alive at 6 months.
The results build on the already-approved relacorilant + nab-paclitaxel doublet — backed by the phase 3 ROSELLA trial, which earned FDA approval in March 2026 and a positive EU recommendation in September 2026. The BELLA trial adds bevacizumab to the mix, and the data suggest the triplet may offer an additional edge, particularly for bevacizumab-naive patients.
By the Numbers:
Why it matters: Platinum-resistant ovarian cancer has very limited treatment options and poor outcomes. The BELLA trial's triplet combination meaningfully outperforms historical benchmarks, and the especially strong results in bevacizumab-naive patients could help guide treatment sequencing decisions for oncologists managing this difficult-to-treat population.
